Conventional liposomes are widely used drug carriers, but they face major limitations. Only a small fraction of the drug reaches the tumor, while a significant portion is trapped in the liver and spleen, reducing therapeutic effectiveness.
Thermosome has overcome this challenge with its thermosensitive liposomes (TSLs), designed for precise, localized drug release. These liposomes contain DPPG2, a proprietary phospholipid that remains stable at body temperature but rapidly releases the drug when exposed to heat.
The treatment process involves hyperthermia, a medical technique that selectively heats the tumor to around 41°C. Once the target temperature is reached, Thermosome’s TSLs are infused intravenously. Upon reaching the heated tumor, the liposomes instantly release high concentrations of the drug directly into the tumor’s blood vessels. This results in up to 15-fold higher local drug concentrations compared to traditional infusion methods, significantly improving therapeutic efficacy.
Beyond direct drug delivery, hyperthermia also has immune-stimulating effects. It enhances the migration of effector T cells to the tumor and triggers the expression of heat shock proteins, improving immune recognition of tumor cells. This dual action – targeted drug delivery and immune activation – makes Thermosome’s technology a game-changer in cancer treatment.
Learn more at Thermosome’s website.
